Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP1 | Q9NZ08 | 8/20 | 0.49 |
| ▸ | ERAP2 | Q6P179 | 7/20 | 0.49 |
| ▸ | LNPEP | Q9UIQ6 | 7/20 | 0.49 |
| ▸ | ITGB2 | P05107 | 4/20 | 0.47 |
| ▸ | ICAM1 | P05362 | 4/20 | 0.47 |
| ▸ | ITGAL | P20701 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12515009 | 0.95 | GHSR (0.47) | ERAP1ERAP2LNPEPKDM4EMAPT | |
| SCHEMBL12515369 | 0.95 | ERAP1 (0.54) | ERAP1ERAP2LNPEPITGB2ICAM1 | |
| SCHEMBL19445891 | 0.95 | ERAP1 (0.54) | ERAP1ERAP2LNPEPITGB2ICAM1 | |
| SCHEMBL21371598 | 0.93 | ERAP2 (0.47) | ERAP1ERAP2LNPEPKDM4EMAPT | |
| SCHEMBL19219738 | 0.93 | GHSR (0.44) | ERAP1ERAP2LNPEPKDM4EMAPT | |
| SCHEMBL19219805 | 0.93 | ERAP2 (0.47) | ERAP1ERAP2LNPEPKDM4EMAPT | |
| SCHEMBL21371584 | 0.93 | ERAP1 (0.57) | ERAP1ERAP2LNPEPITGB2ICAM1 | |
| SCHEMBL19945114 | 0.93 | ERAP1 (0.57) | ERAP1ERAP2LNPEPITGB2ICAM1 | |
| SCHEMBL12515259 | 0.92 | GHSR (0.44) | ERAP1ERAP2LNPEPKDM4EMAPT | |
| SCHEMBL12515258 | 0.92 | ERAP2 (0.47) | ERAP1ERAP2LNPEPKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10603294-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190282521-A1 | Compounds For Use In Treatment Of Mucositis | POLYMEDIX, INC. | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10603294-B2 | Compounds for use in treatment of mucositis | MUC1, FUT6, MMP8 | ERAP1 1190/4885ERAP2 646/4885LNPEP 1252/4885 |
| US-20190282521-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | ERAP1 1190/4885ERAP2 646/4885LNPEP 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.